Barclays PLC Boosts Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Barclays PLC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 541,093 shares of the biotechnology company's stock after acquiring an additional 12,464 shares during the quarter. Barclays PLC owned 0.23% of ADMA Biologics worth $9,279,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics during the 4th quarter valued at $51,000. AlphaQuest LLC acquired a new position in ADMA Biologics during the 4th quarter worth $84,000. Finally, CIBC Private Wealth Group LLC increased its position in shares of ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after purchasing an additional 2,954 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Up 8.9 %

ADMA stock opened at $21.39 on Wednesday. The firm has a market cap of $5.06 billion, a price-to-earnings ratio of 76.39 and a beta of 0.53. ADMA Biologics, Inc. has a 1-year low of $6.23 and a 1-year high of $23.64. The firm has a fifty day moving average price of $18.44 and a two-hundred day moving average price of $18.23. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.